Pirfenidone Viatris Unión Europea - español - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - la pirfenidona - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - inmunosupresores - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Unión Europea - español - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

RIVASTIGMINA VIATRIS 4,6 MG/24H PARCHES TRANSDÉRMICOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

rivastigmina viatris 4,6 mg/24h parches transdérmicos efg

viatris limited - rivastigmina - parche transdÉrmico - 4,6 mg/24 h - rivastigmina 4,6 mg/24 h - rivastigmina

RIVASTIGMINA VIATRIS 9,5 MG/24H PARCHES TRANSDÉRMICOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

rivastigmina viatris 9,5 mg/24h parches transdérmicos efg

viatris limited - rivastigmina - parche transdÉrmico - 9,5 mg/24 h - rivastigmina 9,5 mg/24 h - rivastigmina

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Unión Europea - español - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - besilato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). elevación del segmento st infarto agudo de miocardio, en combinación con aas en los pacientes tratados médicamente elegibles para la terapia trombolítica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. para más información, por favor refiérase a la sección 5.

SITAGLIPTINA VIATRIS 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina viatris 25 mg comprimidos recubiertos con pelicula efg

viatris limited - sitagliptina hidrocloruro - comprimido recubierto con pelÍcula - 25 mg - sitagliptina hidrocloruro 25 mg - sitagliptina

SITAGLIPTINA VIATRIS 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina viatris 50 mg comprimidos recubiertos con pelicula efg

viatris limited - sitagliptina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg - sitagliptina hidrocloruro 50 mg - sitagliptina

SITAGLIPTINA VIATRIS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina viatris 100 mg comprimidos recubiertos con pelicula efg

viatris limited - sitagliptina hidrocloruro - comprimido recubierto con pelÍcula - 100 mg - sitagliptina hidrocloruro 100 mg - sitagliptina

VILDAGLIPTINA VIATRIS 50 MG COMPRIMIDOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vildagliptina viatris 50 mg comprimidos efg

viatris limited - vildagliptina - comprimido - 50 mg - vildagliptina 50 mg - vildagliptina

VILDAGLIPTINA/METFORMINA VIATRIS 50 MG/1.000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vildagliptina/metformina viatris 50 mg/1.000 mg comprimidos recubiertos con pelicula efg

viatris limited - vildagliptina; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - vildagliptina 50 mg; metformina hidrocloruro 1000 mg - metformina y vildagliptina